GSK Overview
Upcoming Projects (GSK)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (GSK)
-
A Second Look: Discussing the potential of the Optilume Benign Prostatic Hyperplasia Catheter and Balloon system from Urotronic and how it compares to medications from Merck, GSK, and Astellas.
Tickers: UROTRONIC, ALPMY, MRK, GSK
Executed On: Sep 01, 2023 at 08:00 AM EDT -
Discussing the potential of the Optilume Benign Prostatic Hyperplasia Catheter and Balloon system from Urotronic and how it compares to medications from Merck, GSK, and Astellas.
Tickers: UROTRONIC, ALPMY, MRK, GSK
Executed On: Aug 25, 2023 at 09:00 AM EDT -
Discussing the SKYSCRAPER-01 trial of tiragolumab in Non Small Cell Lung Cancer (NSCLC) and readthrough to iTeos/GSK's belrestotug
Tickers: ITOS, GSK, RHHBY
Executed On: Jul 14, 2023 at 01:30 PM EDT -
Discussing GSK’s Daprodustat in Chronic kidney disease, ahead of the PDUFA date of 2/1/2023
Ticker: GSK
Executed On: Jan 30, 2023 at 11:00 AM EST -
A Second Opinion: Looking at the topline results of the Phase 2 MISSION trial of zetomipzomib in Lupus Nephritis patients
Tickers: KZR, GSK, AUPH
Executed On: Sep 01, 2022 at 01:00 PM EDT -
A discussion of DREAMM-5 Study (low-dose Blenrep + nirogacestat) in r/r Multiple myeloma
Tickers: SWTX, GSK
Executed On: May 23, 2022 at 01:30 PM EDT
Expired Projects (GSK)
-
Discussing DVAX' HEPLISAV-B vaccine and market potential post approval
Tickers: DVAX, GSK
Execute By: Dec 08, 2017 -
Evaluating the Market Potential of Hua Medicine's HMS5552 in Type II Diabetes Ahead of Mid-Year Phase II Readout. Does the drug have potential to derail the success of major players in the space?
Tickers: HUA MEDICINE, ABT, AZN, NVS, NVO, MRK, SNY, GSK, Lupin Pharmaceuticals, RHHBY
Execute By: May 11, 2016
Upcoming & Overdue Catalysts (GSK)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (GSK)
-
ViiV Healthcare's three-year data on cabotegravir and rilpivirine regimen in mid-stage Phase 2b HIV study released
Tickers: VIIV HEALTHCARE, GSK
Occurred on: Oct 29, 2018 -
IPF: Inhaled αvβ6 inhibitor Phase IIa anticipated to start in 2018
Ticker: GSK
Occurred on: Sep 21, 2018 -
FDA rejects Glaxo's (GSK) Nucala in COPD, raises efficacy issues
Ticker: GSK
Occurred on: Sep 07, 2018 -
US FDA approves GSK's Krintafel (tafenoquine) in preventing the relapse of P. vivax malaria
Ticker: GSK
Occurred on: Jul 20, 2018 -
GSK 165 osteoarthritis Phase II data expected H2 2017
Ticker: GSK
Occurred on: May 22, 2018 -
Extended pharmacology: anti-IL5 mAb – Phase III expected to start in 2018
Ticker: GSK
Occurred on: Mar 19, 2018 -
Results presented from GlaxoSmithKline's (GSK) Nucala (mepolizumab) in asthma control in patients uncontrolled on Xolair (omalizumab)
Ticker: GSK
Occurred on: Mar 05, 2018 -
FDA approves GSK's Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) for adults in the US
Ticker: GSK
Occurred on: Dec 12, 2017 -
IMPACT COPD exacerbation data expected H2 2017
Ticker: GSK
Occurred on: Sep 04, 2017 -
GlaxoSmithKline (GSK) Files New Drug Application in Japan for Shingrix Vaccine in the Prevention of Shingles
Ticker: GSK
Occurred on: Apr 18, 2017 -
Viiv Healthcare Presents Results from 2 Phase 3 Studies Evaluating Dolutegravir + Rilpivirine in HIV Maintenance
Tickers: VIIV HEALTHCARE, PFE, JNJ, GSK, SGIOF
Occurred on: Dec 20, 2016 -
GlaxoSmithKline (GSK) files EU regulatory submission for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD
Ticker: GSK
Occurred on: Dec 02, 2016 -
GlaxoSmithKline (GSK) starts phase III programme with daprodustat for anaemia associated with chronic kidney disease
Ticker: GSK
Occurred on: Nov 24, 2016 -
GlaxoSmithKline's (GSK) Influenza Vaccine FluLaval Quadrivalent Approved by FDA for Expanded Use in Children Ages Six Months and Older
Ticker: GSK
Occurred on: Nov 21, 2016 -
GSK announces positive results in fourth consecutive pivotal trial of Benlysta (belimumab) in SLE
Ticker: GSK
Occurred on: Nov 13, 2016 -
FDA Approves Propeller Health's Platform for use with GlaxoSmithKline's (GSK) Dry Powder Inhaler Ellipta in Patients with Asthma
Tickers: PROPELLER HEALTH, GSK, HKMPF, SFE, SR One, MMM, Social Capital
Occurred on: Nov 07, 2016 -
Regeneron (REGN) and Sanofi's (SNY) Sarilumab for Rheumatoid Arthritis Granted PDUFA date of October 30, 2016 by FDA
Tickers: REGN, JNJ, SNY, GSK
Occurred on: Oct 28, 2016 -
GlaxoSmithKline (GSK) Files FDA Biologics License Application (BLA) for Shingrix Vaccine in the Prevention of Shingles
Ticker: GSK
Occurred on: Oct 24, 2016 -
GlaxoSmithKline (GSK) and Johnson & Johnson (JNJ) Plan to Submit Application to FDA in 2016 for Sirukumab in Rheumatoid Arthritis
Tickers: GSK, REGN, SNY, JNJ
Occurred on: Sep 23, 2016 -
GlaxoSmithKline (GSK) Announces Release of Phase 3 Results for Shingles Vaccine ZOE-70 in New England Journal of Medicine (NEJM)
Ticker: GSK
Occurred on: Sep 15, 2016 -
GlaxoSmithKline (GSK) and Johnson & Johnson (JNJ) Submit Sirukumab in Treatment of Rheumatoid Arthritis to European Medicines Agency
Tickers: GSK, JNJ, SNY, REGN
Occurred on: Sep 12, 2016 -
'Real world’ data shows 83 percent effectiveness for Bexsero in infants in first year of UK national meningitis B immunisation programme
Ticker: GSK
Occurred on: Sep 05, 2016 -
GSK announce positive results from the COPD Salford Lung Study published in the NEJM and presented at European Respiratory Congress
Ticker: GSK
Occurred on: Sep 04, 2016 -
NEJM publishes results of GSK’s long-term LABA safety study of Advair Diskus in children aged 4-11 years with asthma
Ticker: GSK
Occurred on: Sep 01, 2016 -
FDA Approves FLONASE Sensimist Allergy Relief
Ticker: GSK
Occurred on: Aug 03, 2016 -
New Phase III data shows greater treatment response with GSK’s Benlysta (belimumab) vs placebo in patients with highly active SLE
Ticker: GSK
Occurred on: Jun 08, 2016 -
GSK announces phase III study of sirukumab meets both co-primary endpoints in patients with rheumatoid arthritis
Ticker: GSK
Occurred on: Jun 08, 2016 -
StrimvelisTM receives European marketing authorisation to treat very rare disease, ADA-SCID
Ticker: GSK
Occurred on: May 27, 2016 -
Initial Results Expected from Phase 3 Lung Function Study for COPD
Tickers: INVA, GSK
Occurred on: May 24, 2016 -
5 arrested for alleged theft of trade secrets from GlaxoSmithKline (GSK) and Five Prime Therapeutics (FPRX), including data related to FP-1039
Tickers: GSK, FPRX
Occurred on: Jan 20, 2016
Strategic Initiatives (GSK)
-
GlaxoSmithKline (GSK) and VBI Vaccines (VBIV) Enter Research Collaboration to Evaluate VBIV's LPV Platform
Tickers: GSK, VBIV
Announcement Date: Feb 09, 2016
